Expression of androgen receptor is negatively regulated by p531

Neoplasia

Volumn 9, Issue 12, 2007, Pages 1152-1159

  Alimirah, Fatouma ^a   Panchanathany, Ravichandran ^b,c,d   Cheny, Jianming ^b   Zhang, Xiang ^d   Ho, Shuk Mei ^d,e   Choubey, Divaker ^a,b,c,d,e,f  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f Kettering Complex   (United States)

Author keywords

Androgen receptor; DNA damage; p53; Prostate cancer; Transcriptional repression

Indexed keywords

ANDROGEN RECEPTOR; DOXORUBICIN; ETOPOSIDE; LEPTOMYCIN B; PROTEIN P53;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 37149022032     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07769     Document Type: Article

References (51)

1. Nelson WG, De Marzo AM, and Isaacs WB (2003). Prostate cancer. N Eng J Med 349, 366-381.
2. Lee HJ and Chang C (2003). Recent advances in androgen receptor action. Cell Mol Life Sci 60, 1613-1622.
3. Heinlein CA and Chang C (2004). Androgen receptor in prostate cancer. Endocr Rev 25, 276-308.
4. Burnstein KL (2005). Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95, 657-669.
5. Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, et al. (2006). Defining aggressive prostate cancer using a 12-gene model. Neoplasia 8, 59-68.
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, and Sawyers CL (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10, 33-39.
7. Prives C (1998). Signaling to p53: breaking the MDM2-p53 circuit. Cell 95, 5-8.
8. Sharpless NE and DePinho RA (2002). p53: good cop/bad cop. Cell 110, 9-12.
9. Laptenko O and Prives C (2006). Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13, 951-961.
10. Vogelstein B and Kinzler KW (1992). p53 function and dysfunction. Cell 70, 523-526.
11. Oren M and Rotter V (1999). Introduction: p53 - the first twenty years. Cell Mol Life Sci 55, 9-11.
12. Fingerman IM and Briggs SD (2004). p53-Mediated transcriptional activation: from test tube to cell. Cell 117, 690-691.
13. Dai MS, Jin Y, Gallegos JR, and Lu H (2006). Balance of yin and yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia 8, 630-644.
14. Gottlieb TM and Oren M (1996). p53 in growth control and neoplasia. Biochem Biophys Acta 1287, 77-102.
15. Oren M (2003). Decision making by p53: life, death, and cancer. Cell Death Differ 19, 431-442.
16. Li J, Tan M, Li L, Pamarthy D, Lawrence TS, and Sun Y (2005). SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia 7, 312-323.
17. Vousden KH and Lu X (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2, 594-604.
18. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nicholas WW, von Eschenbach AC, and Conti CJ (1993). p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85, 1657-1669.
19. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, and Srivastava S (1995). Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 154, 414-421.
20. Nesslinger NJ, Shi XB, and deVere White RW (2003). Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res 63, 2228-2233.
21. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, and Moul JW (1995). p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1, 1295-1300.
22. Sobel RE and Sadar MD (2005). Cell lines used in prostate cancer research: a compendium of old and new lines - Part 1. J Urol 173, 342-359.
23. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, and Shemshedini L (2001). p53 represses androgen-induced trans-activation of prostate-specific antigen by disrupting hAR amino- to carboxy-terminal interaction. J Biol Chem 276, 38472-38479.
24. Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD, Segawa T, Dobi A, McLeod DG, and Srivastava S (2006). Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 25, 3905-3913.
25. Dumont P, Leu JI, Della Pietra AC, George DL, and Murphy M (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33, 357-365.
26. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, and Vogelstein B (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104, 253-269.
27. Alimirah F, Panchanathan R, Davis FJ, Chen J, and Choubey D (2007). Restoration of p53 expression in human cancer cell lines up-regulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. Neoplasia 9, 427-434.
28. Alimirah F, Chen J, Basrawala Z, Xin H, and Choubey D (2006). DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: Implications for the androgen receptor functions and regulation. FEBS Lett 580, 2294-2300.
29. Alimirah F, Chen J, Xin H, and Choubey D (2006). Androgen receptor auto-regulates its expression by a negative feedback loop through upregulation of IFI16 protein. FEBS Lett 580, 1659-1664.
30. Xin H, Curry J, Johnstone RW, Nickoloff BJ, and Choubey D (2003). Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene 22, 4831-4840.
31. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, and Oyasu R (2001). Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 47, 66-75.
32. D'Souza S, Xin H, Walter S, and Choubey D (2001). The gene encoding p202, an interferon-inducible negative regulator of the p53 tumor suppressor, is a target of p53-mediated transcriptional repression. J Biol Chem 276, 298-305.
33. Wiren KM, Zhang X, Chang C, Keenan E, and Orwoll ES (1997). Transcriptional up-regulation of the human androgen receptor by androgen in bone cells. Endocrinology 138, 2291-2300.
34. Chesire DR and Isaacs WB (2002). Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene 21, 8453-8469.
35. Wu Y, Mehew JW, Heckman CA, Arcinas M, and Boxer LM (2001). Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20, 240-251.
36. Tsui KH, Chang PL, Lin HT, and Juang HH (2004). Down-regulation of prostate of the prostate-specific antigen promoter by p53 in human prostate cancer cells. J Urol 172, 2035-2039.
37. Zhou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, and Srivastava S (2000). p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 275, 6051-6054.
38. Lecane PS, Kiviharju TM, Sellers RG, and Peehl DM (2003). Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate 54, 258-267.
39. Zegarra-Moro OL, Schmidt LJ, Huang H, and Tindall DJ (2002). Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62, 1008-1013.
40. Yang Q, Fung KM, Day WV, Kropp BP, and Lin HK (2005). Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 5, 8-18.
41. Oram SW, Ai J, Pagani GM, Hitchens MR, Stern JA, Eggener S, Pins M, Xiao W, Cai X, Haleem R, et al. (2007). Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia 9, 643-651.
42. Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, and Corey E (2006). Inhibition of androgen-dependent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 8, 862-878.
43. Colombel M, Radvanyi F, Blanche M, Abbou C, Buttyan R, Donehower LA, Chopin D, and Thiery JP (1995). Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 6, 1269-1274.
44. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, and Rosen JM (1995). Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92, 3439-3443.
45. Logan IR, McNeill HV, Cook S, Lu X, Lunec J, and Robson CN (2007). Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate 67, 900-906.
46. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, and Cohen MB (2005). Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 24, 6773-6784.
47. Yang C, Cirielli C, Capogrossi MC, and Passaniti A (1995). Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55, 4210-4213.
48. Ioffe ML, White E, Nelson DA, Dvorzhinski D, and DiPaola RS (2004). Epothilone-induced cytotoxicity is dependent on p53 status in prostate cells. Prostate 61, 243-247.
49. Cronauer MV, Schulz WA, Burchardt T, Ackermann R, and Burchardt M (2004). Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23, 3541-3549.
50. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, and Levine AJ (2000). Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 14, 981-993.
51. Spurgers KB, Gold DL, Coombes KR, Bohnensteiehl NL, Mullins B, Meyn RE, Logothetis CJ, and McDonnell TJ (2006). Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem 281, 25134-25142.